Drug Profile
Research programme: antibacterials - DSTL/Isogenica
Latest Information Update: 30 Jan 2018
Price :
$50
*
At a glance
- Originator Defence Science and Technology Laboratory
- Developer Defence Science and Technology Laboratory; Isogenica
- Class Antibacterials; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections; Clostridium difficile infections; Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 30 Jan 2018 Discontinued for Bacterial infections in England (unspecified route)
- 30 Jan 2018 Discontinued for Clostridium difficile infections in England (unspecified route)
- 30 Jan 2018 Discontinued for Methicillin-resistant Staphylococcus aureus infections in England (unspecified route)